Search for Terms or Answers
Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
For someone who has spent so much of his career recognizing the work of others, it is fitting that Dr. John J. “Jack” Cush should have his own moment in the spotlight.
The American College of Rheumatology (ACR) today issued the following statement in response to the final Medicare Physician Fee Schedule (MPFS) for calendar year 2027 (CY27) from the Centers for Medicare & Medicaid Services (CMS).
Infection remains an important threat to patients with autoimmune and inflammatory diseases. Mitigating this risk is a core duty of the rheumatologist—one that requires us to actively educate patients and advocate for timely vaccination strategies. This article reviews important highlights on
Resolution of dryness remains a key unmet need for patients with Sjögren disease (SjD), as highlighted by the Sjögren SIG session “How to treat SjD” on the final day of APLAR 2026. A rheumatology talk in the session noted that recent phase III trials of ianalumab, dazodalibep and telitacicept
A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern rheumatology care.
At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im (Dongguk University, Korea). The products fall into three tiers: symptom-modifying, biologic/regenerative and structure-oriented. The pipeline is encouraging, but the evidence
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
